Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_assertion type Assertion NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_head.
- NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_assertion description "[Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_provenance.
- NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_assertion evidence source_evidence_literature NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_provenance.
- NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_assertion SIO_000772 26178788 NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_provenance.
- NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_assertion wasDerivedFrom befree-2016 NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_provenance.
- NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_assertion wasGeneratedBy ECO_0000203 NP1290211.RAVjIE_54I9ZPTFCYAG3vf0etNAfFOkSVS-BNSh52geyo130_provenance.